Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study
Journal of the American Academy of Dermatology · 2026-09 · 95 (3) · 814-816
DOI: 10.1016/j.jaad.2026.05.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-09. Verfasst von Ziad Reguiai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Infliximab is used off-label in moderate-to-severe hidradenitis suppurativa (HS).1,2 A subcutaneous (SC) formulation is now available for rheumatoid arthritis, inflammatory bowel disease, axial spondyloarthritis and psoriasis. As it is used off label in HS, data on switching from IV to SC infliximab are lacking. We conducted a retrospective multicenter study across 8 French dermatology centers. All HS patients switched from IV to SC infliximab between August 2021 and October 2025 were included. The decision to switch from IV to SC infliximab was made at the attending physician's discretion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France.
- Department of Dermatology, Military Teaching Hospital Bégin, Saint Mandé, France.
- Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1342, Paris, France; Dermatology Department, APHP, Hôpital Saint-Louis, Paris, France.
- Dermatology Department, APHP, Hôpital Saint-Louis, Paris, France; Department of Dermatology, Hôpital NOVO, Pontoise, France.
- Dermatology Department, APHP, Hôpital Saint-Louis, Paris, France.
- Dermatologic Office, Brest, France.
Zitieren
APA
Reguiai, Z., Fougerousse, A. C., Bachelez, H., Fredeau, L., Grolleau, C., Bouaziz, J. D., Jachiet, M., Mahevas, T., Jouan, N., Pruvost-Balland, C., Sultan, N., Fera, C., Brun, A., Libert, E. P., Fayad Kazour, A., Cassius, C., & HS-France group of the French Society of Dermatology and Reso-Verneuil (2026). Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study. Journal of the American Academy of Dermatology, 95(3), 814-816. https://doi.org/10.1016/j.jaad.2026.05.014
Vancouver
Reguiai Z, Fougerousse AC, Bachelez H, Fredeau L, Grolleau C, Bouaziz JD, et al. Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study. Journal of the American Academy of Dermatology. 2026;95(3):814-816. doi:10.1016/j.jaad.2026.05.014
BibTeX
@article{Reguiai2026,
author = {Reguiai, Ziad and Fougerousse, Anne-Claire and Bachelez, Hervé and Fredeau, Lisa and Grolleau, Chloé and Bouaziz, Jean-David and Jachiet, Marie and Mahevas, Thibault and Jouan, Nicole and Pruvost-Balland, Christelle and Sultan, Nathalie and Fera, Clotilde and Brun, Aurore and Libert, Edgar-Pierre and Fayad Kazour, Alice and Cassius, Charles and HS-France group of the French Society of Dermatology and Reso-Verneuil, HS-France group of the French Society of Dermatology and Reso-Verneuil},
title = {Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {3},
pages = {814--816},
doi = {10.1016/j.jaad.2026.05.014}
}
EUVIMED